Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

DNA molecule - entheon

HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences […]

Read More…